The role of hypertension and renin-angiotensin-aldosterone system inhibitors in bleomycin-induced lung injury

Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ryujiro Hara, Makoto Onizuka, Sawako Shiraiwa, Kaito Harada, Yasuyuki Aoyama, Daisuke Ogiya, Masako Toyosaki, Rikio Suzuki, Sinichiro Machida, Ken Ohmachi, Yoshiaki Ogawa, Hiroshi Kawada, Shigeki Watanabe, Akira Miyajima, Ryota Masuda, Masayuki Iwazaki, Mikio Mikami, Takashi Koike, Hiroyuki Mochizuki, Kiyoshi Ando
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: This real-world study shows that single-agent ibrutinib is an effective therapy for CLL, regardless of age and high-risk molecular features, consistent with clinical trials. Additionally, single-agent ibrutinib was well tolerated, with a low rate of cardiovascular events. This study also emphasized a high molecular testing rate of del(17p)/TP53 mutation and IGHV mutation status in clinical practice according to guideline recommendations.PMID:34511320 | DOI:10.1016/j.clml.2021.07.022
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
In this study, we used the UK Biobank (n = 440,185) to resolve previous ambiguities in the relationship between serum IGF-1 levels and clinical disease. We examined prospective associations of serum IGF-1 with mortality, dementia, vascular disease, diabetes, osteoporosis, and cancer, finding two generalized patterns. First, IGF-1 interacts with age to modify risk in a manner consistent with antagonistic pleiotropy; younger individuals with high IGF-1 are protected from disease, while older individuals with high IGF-1 are at increased risk for incident disease or death. Second, the association between IGF-1 and risk ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSION: Clinically meaningful and durable activity with an acceptable safety profile was observed in participants with relapsed/refractory B-cell malignancies who received single-agent PNT2258.TRIAL REGISTRATION: NCT01733238, first posted 26-Nov-2012. https://clinicaltrials.gov/ct2/show/NCT01733238.PMID:34417162 | DOI:10.1016/j.clml.2021.07.016
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A c...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneo...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conclusion: After allo-HSCT, a significant number of patients developed PTDM and patients with acute graft-versus-host-disease were found to have a higher risk for PTDM. Long-term and continuous follow-up for diabetes and cardiovascular risk factors after HSCT is important in order to be able to provide timely and appropriate treatment.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
Publication date: Available online 18 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kadriye Bahriye Payzin, Kaan Savasoglu, Inci Alacacioglu, Elif Ebru Dalgic, Betul Bolat Kucukzeybek, Aylin Orgen Calli, Sadi Bener, Serdar Payzin
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kadriye Bahriye Payzin, Kaan Savasoglu, Inci Alacacioglu, Elif Ebru Dalgic, Betul Bolat Kucukzeybek, Aylin Orgen Calli, Sadi Bener, Serdar Payzin
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This prospective study assessed the prevalence of pulmonary hypertension (PHT) related to chronic myeloproliferative neoplasms (CMPNs) and evaluated the impact of PHT on survival during long-term follow-up. In a large group of BCR-ABL1 –negative CMPN patients, there was a low prevalence of PHT. The impact of PHT on survival was negligible.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “Wh...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Cancer & Oncology | Hypertension | Leukemia | Lymphoma | Myeloma